Introduction {#Sec1}
============

Increased circulation of fatty acids (FAs) and accumulation of lipids in muscle contributes to glucose intolerance \[[@CR1], [@CR2]\]. Several FA-induced mechanisms of this metabolic defect have been described \[[@CR3]\]. Although it is possible that one of these dominates, a consensus is that these mechanisms are interdependent \[[@CR3]\]. Similar to the negative consequences of FAs, hyperinsulinaemia causes metabolic derangement \[[@CR4], [@CR5]\], possibly because of impaired insulin-responsive GLUT4 regulation. In fact, hyperinsulinaemia-induced GLUT4 dysregulation has been documented in 3T3-L1 adipocytes and L6 myotubes \[[@CR6], [@CR7]\]. Although the details remain to be defined, data from these cells suggest cortical filamentous actin (F-actin) loss, not defects in insulin signalling, as a basis of hyperinsulinaemia-induced GLUT4 dysregulation \[[@CR6], [@CR7]\]. A comparable loss of F-actin is also observed in skeletal muscle obtained from insulin-resistant obese Zucker rats \[[@CR7]\]. These findings complement an emerging appreciation in the field that, while defects in proximal insulin signalling may occur in various insulin-resistant models, distal GLUT4 defects may represent another critical node of impaired glucose metabolism \[[@CR8]--[@CR10]\].

It is well documented that insulin elicits a rapid dynamic remodelling of actin filaments into a cortical mesh, and that this mesh is necessary for GLUT4 translocation \[[@CR9]\]. Also relevant are data that place GLUT4 storage vesicles (GSVs) in the F-actin meshwork, suggesting that this cytoskeletal structure tethers GSVs in the region beneath the plasma membrane (PM), where the final steps of GSV/PM docking and fusion are critically regulated \[[@CR9]\]. Interestingly, cholesterol-enriched regions of the PM have been implicated in regulating F-actin structure \[[@CR11]--[@CR13]\]. While underexplored, cholesterol regulation at the PM is likely to play a very relevant role in GLUT4 regulation. For example, extraction of small (≤30%) amounts of PM cholesterol enhances insulin-stimulated GLUT4 translocation \[[@CR14], [@CR15]\]. The cholesterol-dependent gain in PM GLUT4 resulting from a small decrease in PM cholesterol is not associated with an inhibition of endocytosis \[[@CR14], [@CR15]\], but this does occur with extraction of larger amounts \[[@CR14]--[@CR17]\].

These findings prompted this study to examine membrane/cytoskeletal features under in vivo and in vitro conditions of FA-induced insulin resistance. Herein, data suggest that excess FAs induce the accrual of skeletal muscle membrane cholesterol and that this provokes a loss in F-actin that plays a critical role in GLUT4 translocation. Data further indicate that the accumulation of membrane cholesterol results from increased hexosamine biosynthesis pathway (HBP) activity engaging a cholesterologenic transcriptional response. Adding to the notion that defects other than those in proximal insulin signalling contribute to insulin resistance, it was found that cholesterol lowering rescues F-actin and GLUT4 responsiveness, but not defects in insulin signalling. Together, these data highlight the hitherto unappreciated importance of membrane/cytoskeletal derangement in GLUT4 dysfunction in insulin resistance.

Methods {#Sec2}
=======

**Animals** Male C57/BL6J mice (Jackson Laboratory, Bar Harbor, ME, USA), 4 weeks old, were assigned to two groups for 4 weeks of treatment. Control mice (*n* = 3) received a diet containing 18% energy from protein, 78% energy from carbohydrates and 4% energy from fat (Harlan, Indianapolis, IN, USA). High-fat-fed mice (*n* = 3) received a diet containing 17% energy from protein, 43% energy from carbohydrates, and 41% energy from fat (Research Diets, New Brunswick, NJ, USA). Hind-limb muscles were dissected out, blotted on gauze, rinsed in NaCl, and immersed in 4% paraformaldehyde/phosphate buffer (vol./vol.) (soleus) or frozen in liquid nitrogen (gastrocnemius). Ossabaw miniature swine (Purdue-Indiana University School of Medicine Comparison Medicine Program, Indianapolis, IN, USA), 3 months old, were assigned to two groups for 55 weeks of treatment. Control swine (*n* = 9) received a standard lean chow diet containing 22% energy from protein, 70% energy from carbohydrates and 8% energy from fat (TestDiet, Richmond, IN, USA). Control swine ate 6.276 MJ/day (1,500 kcal/day) until 6 months of age, then 10.46 MJ/day (2,500 kcal/day) until they were killed. Similar to the methods in previous reports from Dyson et al. and Sturek et al. \[[@CR18], [@CR19]\], obese swine (*n* = 9) received a high-fat feed composed of lean chow supplemented with (all wt/wt): cholesterol 2.0%, hydrogenated soyabean oil 47.6% (contains 56% *trans* FAs), corn oil 2.5%, and sodium cholate 0.7%. This mixture yielded a composition of 10% energy from protein, 17% energy from carbohydrates and 73% energy from fat. Pigs in the obese group ate ∼12.550--13.390 MJ/day (3,000--3,200 kcal/day) until 6 months of age, then 29.290--32.640 MJ/day (7,000--7,800 kcal/day) until they were killed. All animals were housed in individual cages/pens with a 12 h light--dark cycle. Water was provided ad libitum. Fasting plasma glucose and insulin were determined from blood samples drawn from conscious pigs to calculate the HOMA value for insulin resistance \[[@CR18]\]. All animal protocols were approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee.

**Cell culture** Rat L6 skeletal muscle cells that stably express GLUT4 and carry an exofacial myc-epitope (L6-GLUT4myc; generously obtained from A. Klip, Hospital for Sick Children, Toronto, ON, Canada) were cultured as described by McCarthy et al. \[[@CR7]\]. All studies used myotubes 4--6 days after initiation of differentiation. Palmitate induction of insulin resistance was performed by treating cells with palmitate conjugated to FA-free BSA (MP Biomedicals, Solon, OH, USA) as detailed by Chavez et al. \[[@CR20]\]. Briefly, palmitate was dissolved in ethanol at a concentration of 75 mmol/l. For each experiment this stock was diluted (1:25) to 3 mmol/l in 1% FBS-DMEM containing 2% BSA (wt/vol.), sonicated, and incubated at 55°C for 10 min. Dilutions of this were then prepared in 1% FBS/DMEM/2% BSA, cooled to room temperature, filter sterilised, and used to treat myotubes for 15--16 h. To test if inhibition of glutamine:fructose-6-phosphate amidotransferase (GFAT) with 6-diazo-5-oxo-[l]{.smallcaps}-norleucine (DON; Sigma, St Louis, MO, USA) protected against the palmitate-induced defects, 0 or 20 μmol/l DON was included in the overnight incubation medium. Prior to all experiments, cells were serum starved for 60 min. All acute treatments occurred during the final 5--30 min of serum starvation, as indicated.

**Human biopsies** Percutaneous needle biopsies of the vastus lateralis were obtained from seven individuals (five men/two women; BMI 27.9 ± 1.7 kg/m^2^, \[range 22.5--34 kg/m^2^\]; age 37.29 ± 4.49 years \[range 19--53 years\]) in whom insulin sensitivity was determined by hyperinsulinaemic--euglycaemic clamp \[[@CR21]\]. All individuals gave informed consent for these studies, which were approved by the Indiana University-Purdue University Institutional Review Board.

**Glucose transport** Cells were incubated in glucose-free buffer (125 mmol/l NaCl, 5 mmol/l KCl, 1.8 mmol/l CaCl~2~, 2.6 mmol/l MgSO~4~, 25 mmol/l HEPES, 2 mmol/l pyruvate, 2% BSA) for 30 min, then either left in the basal state or stimulated with 100 nmol/l insulin for 20 min as described by McCarthy et al. \[[@CR7]\]. Uptake was initiated with the addition of 2-deoxy\[1,2,-^3^H\]glucose (2.035 kBq/μl; Perkin Elmer, Boston, MA, USA). Non-specific uptake was quantified via cell-associated radioactivity in the presence of 20 μmol/l cytochalasin B. After 5 min, uptake was terminated via four quick washes with ice-cold PBS. Cells were solubilised in 1 mol/l NaOH and \[^3^H\] was measured by liquid scintillation. Counts were normalised to total cellular protein, as determined by the Bradford method.

**Membrane analyses** A PM-enriched fraction was prepared as described by Khayat et al*.* \[[@CR22]\]. Briefly, myotubes were harvested in a homogenisation buffer (250 mmol/l sucrose, 20 mmol/l HEPES, 2 mmol/l EGTA and 3 mmol/l NaN~3~, pH 7.4) containing freshly added protease inhibitors (200 μmol/l PMSF, 1 μmol/l leupeptin and 1 μmol/l pepstatin A) and homogenised through a 22 gauge needle ten times. The homogenate was centrifuged at 760 *g* for 5 min at 4°C, and the supernatant fraction was centrifuged at 31,000 *g* for 20 min to separate a PM-enriched pellet from an intracellular microsome supernatant fraction. The PM pellet was resuspended in homogenisation buffer. Protein and cholesterol contents were determined by the Bradford and Amplex Red methods as described by Chen et al. \[[@CR14]\]. Several analyses revealed that changes in PM cholesterol were similarly reflected in total membrane fractions prepared by centrifuging the original homogenate at 5,000 *g* for 20 min and then subjecting the supernatant fraction to 100,000 *g* for 30 min. As the number of cells required to obtain this total membrane fraction was half that required to prepare PM-enriched fractions, we used total membrane fractions.

**SDS-PAGE analyses** Cell extracts were prepared from 10 cm diameter dishes. Myotubes were washed two times with ice-cold PBS and scraped into 1 ml lysis buffer (25 mmol/l Tris, pH 7.4, 50 mmol/l NaF, 10 mmol/l Na~3~P~2~O~7~, 137 mmol/l NaCl, 10% glycerol, 1% Nonidet P-40) containing 2 mmol/l PMSF, 2 mmol/l Na~3~VO~4~, 5 μg/ml aprotinin, 10 μmol/l leupeptin and 1 μmol/l pepstatin A, then rotated for 15 min at 4°C. Insoluble material was separated from the soluble extract by centrifugation for 15 min at 4°C. Protein concentrations were determined via the Bradford method and equivalent protein amounts were loaded onto a 7.5% acrylamide gel. The resolved fractions were transferred to nitrocellulose (Bio-Rad, Hercules, CA, USA). Phosphorylated-protein kinase B \[PKB/Akt2\], -Akt substrate of 160 kDa (AS160), -insulin receptor (IR) and -IRS1 proteins were detected with anti-phospho-Akt2 (Ser474) (Genscript, Piscataway, NJ, USA), anti-phospho-Akt substrate (PAS) (Cell Signaling, Danvers, MA, USA), and anti-phosphotyrosine (PY20) (BD Biosciences, Lexington, KY, USA), respectively. Equal loading was confirmed by Ponceau staining and immunoblot analysis with anti-Akt antibody (Stressgen Bioreagents, Victoria, BC, Canada) and anti-actin antibody (Cytoskeleton, Denver, CO, USA). All immunoblots were labelled with IR-conjugated secondary antibody and analysed via the Odyssey imaging system (LI-COR, Lincoln, NE, USA).

**Immunocytochemistry** Labelling of isolated soleus muscle and myotubes was performed as described by McCarthy et al. \[[@CR7]\]. Briefly, tissues were fixed for 2 h and then permeabilised. Paired tissue sections were rinsed three times in PBS and blocked in 5% milk/PBS/0.05% Tween. Tissues were then incubated with anti-F-actin antibody and extensively washed with PBS prior to incubation for 60 min at room temperature in Rhodamine Red-X-conjugated donkey anti-mouse IgM. Tissues were again subjected to an extensive PBS wash and then a quick rinse in double-distilled H~2~O. Tissues were mounted in Vectashield and analysed via confocal microscopy (LSM 510 NLO; Zeiss, Thornwood, NY, USA). Myotubes were fixed and left unpermeabilised (L6-GLUT4myc) or permeabilised (F-actin, O-linked *N*-acetylglucosylation) in 0.2% Triton X-100/PBS and blocked in Odyssey blocking buffer. The samples were then incubated with anti-c-myc antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), β-actin-specific mouse IgM anti-human F-actin antibody (Serotec, Oxford, UK), and anti-O-linked *N*-acetylglucosamine isolated from rat liver (RL2) antibody (Affinity Bioreagents, Golden, CO, USA). After overnight labelling, cells were washed and incubated with infrared-conjugated secondary antibodies. Images were collected and quantified with the Odyssey imaging system. Immunofluorescent intensity was normalised to Syto60 nucleic acid staining (Molecular Probes, Carlsbad, CA, USA). All microscope/camera settings were identical between groups.

**RNA isolation and RT-PCR** Cells were lysed using a Qiagen (Qiagen, Valencia, CA, USA) QIAshredder and RNA was isolated using a Qiagen RNeasy mini kit. RNA (500 ng--1.0 μg) was reversed transcribed with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) to produce an RT-PCR template. Reactions were performed in a 96 well plate format using the ABI Prism 7000 Sequence Detection System. Each reaction contained the following: 12.5 μl SYBR Green, 500 nmol/l of each primer, 5 μl cDNA (from the cDNA synthesis reaction), and RNase-free water up to a total volume of 25 μl. Data are expressed relative to *Gapdh* using the ΔΔC~t~ method. See Electronic supplementary material (ESM) Table [1](#MOESM1){ref-type="media"} for primer sequences used to detect *Acaca*, *Fasn*, *Gapdh*, *Hmgcr* and *Hmgcs1* genes.

**Statistics** All values are presented as means ± SE. The significance of differences between means was evaluated by one-way repeated-measures ANOVA. Where differences among groups were indicated, the Neumann--Keuls test was used for post hoc comparison between groups. Differences between two groups were analysed using the Student's *t* test for independent samples. GraphPad Prism 5 software was used for all analyses. *p* \< 0.05 was considered significant.

Results {#Sec3}
=======

**Muscle membrane cholesterol is elevated in glucose-intolerant animals and humans** High-fat feeding of C57BL/6J mice for 4 weeks, which has been reported to induce insulin resistance \[[@CR23]--[@CR25]\], induced an increase in skeletal muscle membrane cholesterol compared with controls (Fig. [1a](#Fig1){ref-type="fig"}). This accrual of skeletal muscle membrane cholesterol was also observed in high-fat-fed Ossabaw swine (Fig. [1b](#Fig1){ref-type="fig"}). HOMA values shown in Fig. [1](#Fig1){ref-type="fig"}c confirm the insulin-resistant phenotype of this Ossabaw swine model \[[@CR18], [@CR19]\]. Human muscle biopsies from individuals across a range of insulin sensitivities revealed an inverse correlation between membrane cholesterol content and glucose disposal rate (Fig. [1d](#Fig1){ref-type="fig"}). From the mouse soleus muscle used to measure cholesterol (Fig. [1a](#Fig1){ref-type="fig"}), a thin slice was obtained to image F-actin. Fig. [1](#Fig1){ref-type="fig"}e shows that high-fat feeding was associated with a loss of F-actin. Using cultured L6 myotubes, the study next examined the insulin-desensitising effect of palmitate on GLUT4/glucose transport regulation and whether cholesterol accrual and/or F-actin loss were components of this effect.Fig. 1Glucose-intolerant humans and animal models display skeletal muscle membrane cholesterol accrual. Skeletal muscle membrane cholesterol from control and high-fat-fed C57/B6 mice (**a**) and Ossabaw swine (**b**). HOMA values in the Ossabaw swine (**c**). Plot of glucose disposal rate and skeletal membrane cholesterol from humans with a range of insulin sensitivities assessed by hyperinsulinaemic--euglycaemic clamp (**d**); *r* = −0.7857; *p* = 0.048. Cortical F-actin from skeletal muscle from control and high-fat-fed C57/B6 mice (**e**). Values are means ± SE from three mice and nine swine per experimental group, and three to five images of F-actin/area from three to five separate experiments. \**p* \< 0.05 vs control group. C, control; HF, high-fat; IF, immunofluorescence. Scale bar, 10 μm

**Palmitate induces glucose transport system dysregulation in muscle cells** Exposure of L6-GLUT4myc myotubes to increasing concentrations of palmitate (C16:0, a saturated FA documented to be a prevalent lipid in rat muscle \[[@CR26]\] and to desensitise muscle and cultured myotubes to the metabolic effects of insulin \[[@CR27], [@CR28]\]) resulted in an impairment in insulin-stimulated L6-GLUT4myc translocation (Fig. [2a](#Fig2){ref-type="fig"}). Recapitulating the findings of others, the palmitate-induced defect was significant at 300 μmol/l, a concentration in the upper range of human physiology \[[@CR29], [@CR30]\]. Whereas higher concentrations of this lipid were associated with a recognised increase in basal GLUT4 translocation and glucose transport (data not shown), this was not the case with the physiological concentration of palmitate (Fig. [2b](#Fig2){ref-type="fig"}). All subsequent investigations of insulin action and membrane/cytoskeletal features used 300 μmol/l palmitate. Consistent with the negative effect of palmitate on insulin-regulated GLUT4 translocation, insulin-stimulated glucose transport was reduced by 36% (Fig. [2c](#Fig2){ref-type="fig"}).Fig. 2Palmitate induces insulin resistance in L6 myotubes. Incubation of L6 myotubes in the presence of palmitate (C16:0) for 16 h impairs insulin-stimulated GLUT4 translocation (**a**, **b**) and 2-deoxyglucose uptake (**c**). White bars, basal; black bars, insulin-stimulated for 20 min. Values are means ± SE from 3--12 separate experiments. \**p* \< 0.05 vs control group; ^†^*p* \< 0.05 vs control insulin group. 2-DG, 2-deoxyglucose; IF, immunofluorescence

**Palmitate-induced insulin-resistant myotubes display increased membrane cholesterol** Analogous to the animal and human findings, membranes prepared from the palmitate-induced insulin-resistant myotubes displayed a 27% increase in cholesterol and a 33% decrease in F-actin as compared with controls (Fig. [3a, b](#Fig3){ref-type="fig"}). Removal of this excess cholesterol with a low dose (0.1 mmol/l) of methyl-β-cyclodextrin (βCD) decreased membrane cholesterol in palmitate-treated myotubes to levels 14% lower than control (Fig. [3a](#Fig3){ref-type="fig"}). As seen in Fig. [3b](#Fig3){ref-type="fig"}, this βCD-induced lowering of membrane cholesterol increased F-actin above control by 10% (*p* = 0.159 \[i.e. trend\]). Propidium iodine staining suggested the low dose of βCD did not affect cell viability (ESM Fig. [1](#MOESM2){ref-type="media"}). Importantly, the cholesterol lowering/normalisation of F-actin fully restored insulin-stimulated GLUT4 translocation and glucose transport in palmitate-treated myotubes (Fig. [3c, d](#Fig3){ref-type="fig"}).Fig. 3Cholesterol lowering improves cortical F-actin and insulin responsiveness impaired by palmitate. Membrane cholesterol (**a**), cortical F-actin (**b**), L6-GLUT4myc (**c**) and 2-deoxyglucose uptake (**d**) from control and palmitate-treated L6 myotubes co-treated without or with βCD. White bars, basal; black bars, insulin-stimulated for 20 min. Values are means ± SE from 3--28 separate experiments. \**p* \< 0.05 vs control basal group; ^†^*p* \< 0.05 vs control insulin group. 2-DG, 2-deoxyglucose; IF, immunofluorescence

**Exogenously added cholesterol promotes F-actin loss and GLUT4 dysregulation** Exogenous-cholesterol-loading experiments were performed to confirm directly the negative impact of excess membrane cholesterol on F-actin and glucose transport regulation. Treatment of control myotubes with βCD conjugated to cholesterol (βCD:Chol) increased membrane cholesterol (Fig. [4a](#Fig4){ref-type="fig"}) and decreased F-actin (Fig. [4b](#Fig4){ref-type="fig"}). These defects were associated with a concomitant decrease in insulin-stimulated GLUT4 translocation and glucose transport (Fig. [4c, d](#Fig4){ref-type="fig"}). Note the loss in GLUT4 responsiveness induced by βCD:Chol was similar to that induced by palmitate (24.64 ± 3.968 \[*n* = 14\] vs 26.76 ± 3.932% \[*n* = 44\]; *p* = 0.7746). In addition, although appearing more moderate, the loss in glucose transport induced by βCD:Chol was not statistically different from that induced by palmitate (19.59 ± 8.778 \[*n* = 3\] vs 30.90 ± 3.229% \[*n* = 18\]; *p* = 0.2065). Admittedly, testing of the effect of βCD:Chol on transport may have been underpowered. However, Fig. [4](#Fig4){ref-type="fig"}e indicates that the insulin-stimulated fold response was decreased by 38% with βCD:Chol (*p* = 0.1338 \[i.e. trend\]) and thus, collectively, these analyses suggest that exogenous cholesterol loading induces a palmitate-like insulin resistance.Fig. 4Exogenous cholesterol membrane loading suppresses insulin-stimulated PM GLUT4 and glucose transport. Membrane cholesterol (**a**), F-actin (**b**), L6-GLUT4myc (**c**) and 2-deoxylglucose uptake (**d**, **e**) in L6 myotubes treated with or without 5 mmol/l βCD:cholesterol. White bars, basal; black bars, insulin-stimulated for 20 min. Values are means ± SE from 3--14 separate experiments. \**p* \< 0.05 vs control basal; ^†^*p* \< 0.05 vs. control insulin group; ^‡^*p* = 0.1338. The significance of difference between fold insulin-stimulated 2-deoxyglucose transport values was evaluated by a paired one-tailed *t* test. 2-DG, 2-deoxyglucose; Chol, cholesterol

**Defective signal transduction appears independent of membrane cholesterol accrual** Myotubes treated with 100 nmol/l insulin for 5 min displayed an approximately fourfold increase in Akt2 phosphorylation at serine 474 (Fig. [5](#Fig5){ref-type="fig"}). As is well documented \[[@CR28]\], palmitate treatment caused a decrease in phosphorylation of Akt2 (Fig. [5](#Fig5){ref-type="fig"}), the isoform primarily responsible for insulin-stimulated glucose transport \[[@CR31]\]. Strikingly, the positive effect of βCD-mediated cholesterol removal on palmitate-impaired GLUT4 translocation and glucose transport (Fig. [3c, d](#Fig3){ref-type="fig"}) was not associated with a rescue of the palmitate-induced defect in Akt2 phosphorylation (Fig. [5](#Fig5){ref-type="fig"}). Consistent with the observations of others \[[@CR8]\], insulin-stimulated IR and IRS-1 phosphorylation remained intact in palmitate-treated myotubes, yet in support of an uncorrectable Akt2 dysfunction, phosphorylation of the Akt2 substrate AS160 was impaired by palmitate and not corrected by βCD (ESM Fig. [2](#MOESM3){ref-type="media"}).Fig. 5Impaired insulin signalling is not rescued by cholesterol lowering. Basal and insulin-stimulated Akt2 phosphorylation in control and palmitate-treated L6 myotubes co-treated without or with βCD. White bars, basal; black bars, insulin-stimulated for 5 min. Values are means ± SE from five to seven separate experiments. \**p* \< 0.05 vs control basal; ^†^*p* \< 0.05 vs control insulin group

**Increased O-linked glycosylation engages a cholesterolgenic response that contributes to membrane/cytoskeletal defects and insulin resistance** A previous study has shown that lipid infusion in rats \[[@CR32]\] and direct palmitate treatment in myotubes \[[@CR33]\] elevates glucose flux through the HBP. Moreover, the HBP has recently been implicated in hyperinsulinaemia-induced membrane cholesterol accrual, F-actin loss and insulin resistance in 3T3-L1 adipocytes \[[@CR34]\]. Palmitate-treated myotubes displayed a 24% increase in O-linked glycosylation, an end-product of the HBP, as determined via anti-RL2 immunofluorescence (Fig. [6a, b](#Fig6){ref-type="fig"}). With regard to cholesterol synthesis, it has been shown that HBP activity increases specificity 1 (Sp1) DNA-binding activity \[[@CR33]\]. A prediction of this modification is induction of FA synthetic and, albeit to a lesser extent, cholesterol synthetic genes \[[@CR35]\] through Sp1-mediated coactivation of sterol regulatory element-binding protein (SREBP)-1c \[[@CR36]\]. The transcript level of *Hmgcr*, which encodes 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGR), a rate-limiting enzyme in cholesterol synthesis, was elevated by palmitate (Fig. [6c](#Fig6){ref-type="fig"}). Use of an antibody that recognises HMGR also suggested that palmitate-treated cells displayed a corresponding elevation in HMGR protein, yet the intensity of the bands detected was too low for accurate analysis. Inhibition of palmitate-induced HBP activity with the HBP inhibitor 6-diazo-5-oxo-[l]{.smallcaps}-norleucine (DON) lowered O-linked glycosylation, *Hmgcr* transcript and membrane cholesterol to or below levels observed in control cells (Fig. [6a--d](#Fig6){ref-type="fig"}). This was accompanied by an increase in F-actin and a correction of insulin-regulated glucose transport (Fig. [6e, f](#Fig6){ref-type="fig"}).Fig. 6Palmitate induces HBP flux and *Hmgr* transcription in L6 myotubes. **a**, **b** Anti-RL2-detected O-linked glycosylation immunofluorescence in: control myotubes, palmitate-treated myotubes and palmitate and DON-treated myotubes. *Hmgr* transcription (**c**), membrane cholesterol (**d**), cortical F-actin (**e**) and insulin-stimulated 2-deoxyglucose transport (**f**) from control and palmitate-treated L6 myotubes in the absence or presence of DON. Images were taken at ×60 magnification. Values are means ± SE from 3--13 separate experiments. \**p* \< 0.05 vs non-treated control; ^†^*p* \< 0.05 vs non-treated palmitate group

Discussion {#Sec4}
==========

While the derangements that contribute to glucose intolerance are certainly numerous and complex, work throughout the field has highlighted the detrimental effects of saturated FAs, and particularly palmitate, on glucose metabolism in skeletal muscle. Data presented here suggest that membrane cholesterol accrual may play a contributing role in obesity-associated glucose intolerance. Mechanistically, the cholesterol-laden membrane compromises F-actin structure, documented by several laboratories to be an essential feature of insulin and GLUT4 action \[[@CR6], [@CR7], [@CR37]--[@CR39]\]. Data also suggest increased HBP activity as a molecular basis for the membrane cholesterol accrual via engagement of a cholesterolgenic programme.

Interestingly, the palmitate-induced decrease in insulin signalling to Akt2 and AS160 was not as damaging as would be predicted or not yet advanced to a level to compromise GLUT4 regulation. Surprisingly, correction of the membrane/cytoskeletal defect completely restored the palmitate-induced defect in GLUT4/glucose transport regulation, but not the Akt2/AS160 impairment. This view is supported by recent analyses showing that the maximal effect of insulin on GLUT4 translocation in L6 myotubes occurs at insulin concentrations where only 5% of the total Akt pool is phosphorylated \[[@CR8]\]. Moreover, treatments with lower palmitate concentrations (\<300 μmol/l) were found to still impair insulin-regulated GLUT4 translocation, yet insulin signalling remained intact. Therefore, these data support a membrane/cytoskeletal defect beyond proximal insulin signalling as a major GLUT4/glucose transport system deregulator.

With regard to the cholesterolgenic model of insulin resistance suggested herein, while we found a significant elevation in the expression of *Hmgcr* with palmitate, the expression of other SREBP-1-regulated genes (e.g. *Acaca*, *Fasn* and *Hmgcs1*) did not consistently follow the same pattern of expression (ESM Fig. [3](#MOESM4){ref-type="media"}). For example, whereas the transcript level of *Acaca* was increased by palmitate, levels of *Fasn* and *Hmgcs1* were not. These variations may result from the differing contributions of the two splice variants of SREBP-1 (1a and 1c) in the control of lipogenic transcription, as it has been documented that SREBP-1a and SREBP-1c have differing levels of control over these genes \[[@CR40], [@CR41]\]. These experiments also found that DON was ineffective in preventing the palmitate-induced increase in *Acaca*. Unfortunately, we did not measure diacylglycerol or triacylglycerol levels. Nevertheless, DON treatment prevented the palmitate-induced cholesterolgenic response, lending support to a membrane cholesterol-induced, rather than a lipid-induced, state of insulin resistance. Moreover, removal of the excess membrane cholesterol with βCD prevented the membrane/cytoskeletal defect and GLUT4/glucose transport dysregulation. Interestingly, this tactic did not restore insulin signalling, perhaps suggesting that an increase in intramyocellular lipids is occurring and is the basis for the palmitate-induced impairment in insulin signalling. These observations suggest high-fat-feeding-induced cholesterol, but not diacylglycerol/triacylglycerol, accrual compromises membrane/cytoskeletal mechanisms important for glucose transport.

The concept that increased HBP activity might provoke insulin resistance via a SREBP response is supported by recent data showing that inhibition of SREBP improves insulin resistance in high-fat-fed mice \[[@CR42]\]. Whether this is a SREBP/HMGR response is not clear, but our work would suggest this to be a possibility. In addition to HBP activity possibly increasing SREBP transcript via O-linked *N*-acetylglucosylation of Sp1 \[[@CR33], [@CR36]\], the HBP has also been implicated in increased liver X receptor-dependent activation of the SREBP-1c promoter \[[@CR43]\]. Given the complexity of the transcriptional control of cholesterol synthesis, nuclear analyses dissecting how the HBP provokes membrane cholesterol toxicity are currently under way.

It should be noted that the high-fat diets we employed for the swine and mice contained 2% and 0.2% cholesterol, respectively. This difference in dietary cholesterol amount did not equate to a similar difference in muscle membrane cholesterol accrual. For example, the high-fat-fed swine that consumed more cholesterol displayed a lower increase in muscle membrane cholesterol than the mice fed a high-fat diet containing far less cholesterol. As mammalian cells contain an intricate feedback system that senses the level of membrane cholesterol and modulates the transcription of genes that mediate cholesterol synthesis and uptake \[[@CR44]\], it is likely that circulating cholesterol does not contribute to muscle membrane cholesterol content. In fact, these data seem to collectively place the HBP as a central participant in peripheral cholesterol toxicity.

It is possible that the F-actin changes are localised in cholesterol-enriched caveolae microdomain membrane regions. Intriguingly, imaging analyses from this study support the observed reciprocal changes in membrane cholesterol and F-actin. Notably, F-actin labelling has been documented in electron micrographs to be localised in caveolae regions \[[@CR45]\]. While caveolae have been postulated to contribute to many functions in insulin and GLUT4 action through the years \[[@CR9]\], these findings must be cautiously interpreted. Concerns regarding the study of caveolae are associated with each of the numerous strategic approaches used to study these structures. In spite of these caveats, fluorescence confocal labelling of caveolae and F-actin have revealed actin filaments emanating from caveolae microdomains \[[@CR11]\]. Moreover, quantitative electron microscopy and freeze-fracture analyses have revealed that cytoskeletal components, including actin, are highly enriched in the membrane area underlying the neck part of caveolae \[[@CR12]\]. These findings assign caveolae a critical role in the functionality of F-actin organisation. Given the unequivocal importance of F-actin in insulin-regulated GLUT4 translocation, these findings also emphasise the importance of caveolae in GLUT4 regulation.

Of interest to our understanding of caveolae-associated actin regulation are new electron microscopic data showing high concentrations of phosphatidylinositol 4,5-bisphosphate (PIP~2~) at the rim of caveolae \[[@CR46]\]. This localisation of PIP~2~ is consistent with its regulation of the cytoskeleton where the availability of this lipid is recognised to modulate membrane/cytoskeleton interaction, the stability of F-actin and the turnover of stress fibres \[[@CR47]\]. Interestingly, reduced PM PIP~2~ and F-actin structure are observed in hyperinsulinaemia-induced insulin-resistant 3T3-L1 adipocytes and L6 myotubes. In these cells insulin-stimulated GLUT4 translocation is impaired, but can be corrected with exogenous PIP~2~ addition to the PM that mediates a restoration of F-actin structure \[[@CR6], [@CR7]\].

In striking similarity to our myotube findings, an approximate 40% reduction in insulin-stimulated muscle glucose transport has been seen as early as 5 weeks in C57Bl/6J mice fed a high-fat diet \[[@CR23]\] and, at the 4 week interval, muscle insulin resistance in these animals is also suggested by a marked decrease in glucose disposal rate with no change in hepatic glucose production \[[@CR24]\]. Interestingly, insulin-stimulated Akt phosphorylation shows a trend to be decreased by 4 weeks of high-fat feeding, though this effect did not reach statistical significance until after 8 weeks; a similar pattern was observed in liver tissue \[[@CR25]\]. Ongoing studies are now specifically evaluating the temporal sequence of membrane/cytoskeletal and signal transduction derangements in skeletal muscle from high-fat fed animals. A prediction we favour is that membrane/cytoskeletal derangement occurs before signal dysfunction and this early event may contribute to the initial loss of insulin sensitivity.

In summary, these data suggest that a contributing factor in the pathogenesis of glucose intolerance might involve an accrual of skeletal muscle membrane cholesterol and a resultant defect in membrane/cytoskeletal function. Interestingly, this membrane/cytoskeletal defect seems to occur concomitantly with impaired insulin signal propagation in the L6 myotube system. Nevertheless, the later derangement was not limiting, as correction of membrane cholesterol excess mitigated cytoskeletal dysfunction and GLUT4 responsiveness, while signalling remained impaired. Collectively, these findings implicate a reversible abnormality (i.e. elevated cholesterol synthesis/accrual) that may be an early defect that could be targeted to improve glucose disposal.
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Supplemental Table 1(PDF 52 kb)Fig. S1High, but not low, concentrations of βCD alter plasma membrane integrity. L6 myotubes were treated with increasing concentrations of βCD for 30 min. Whole cells were stained with propidium iodide. All microscope and camera settings were identical between groups and images were collected at ×60 magnification. These are representative images from 2 independent experiments (PDF 88 kb)Fig. S2Palmitate does not impair insulin signaling to IR and IRS1, yet signaling beyond Akt-2 to AS160 is defective. Basal and insulin-stimulated IR (**a**), IRS1 (**b**), and AS160 (**c**, **d**) phosphorylation in control and palmitate-treated L6 myotubes co-treated without or with βCD. A representative immunoblot is shown from 3--5 independent experiments. Open bars, basal; closed bars, 5 min insulin stimulated. Values are means ± SE from 5--7 separate experiments. \**P* \< 0.05 vs. control basal, ^\#^*P* \< 0.05 vs. control insulin group (PDF 56 kb)Fig. S3Palmitate displays effects on *Acaca*, but not *Fasn*, transcription in L6 myotubes that is not suppressed by DON. *Acaca* (**a**), *Hmgcs1* (**b**), and *Fasn* (**c**), transcription from control and palmitate-treated L6 myotubes in the absence or presence of DON. Values are means ± SE from 3--19 separate experiments. \**P* \< 0.05 vs. control (PDF 22 kb)
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